Symbols / RXRX Stock $3.51 +0.29% Recursion Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
RXRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Najat Khan Ph.D.
Exch · Country NMS · United States
Market Cap 1.85B
Enterprise Value 1.19B
Income -644.76M
Sales 74.68M
FCF (ttm) -208.52M
Book/sh 2.14
Cash/sh 1.41
Employees 600
Insider 10d —
IPO Apr 16, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.12
PEG —
P/S 24.83
P/B 1.64
P/C —
EV/EBITDA -2.10
EV/Sales 15.88
Quick Ratio 5.20
Current Ratio 5.50
Debt/Eq 6.89
LT Debt/Eq —
EPS (ttm) -1.44
EPS next Y -0.85
EPS Growth —
Revenue Growth 6.82%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-02-25
ROA -27.72%
ROE -59.54%
ROIC —
Gross Margin 0.00%
Oper. Margin -3.29%
Profit Margin 0.00%
Shs Outstand 521.95M
Shs Float 510.29M
Insider Own 2.85%
Instit Own 64.59%
Short Float 34.94%
Short Ratio 14.00
Short Interest 174.40M
52W High 7.18
vs 52W High -51.11%
52W Low 2.80
vs 52W Low 25.36%
Beta 1.01
Impl. Vol. 0.78%
Rel Volume 0.58
Avg Volume 16.08M
Volume 9.35M
Target (mean) $6.71
Tgt Median $6.00
Tgt Low $3.00
Tgt High $11.00
# Analysts 7
Recom Buy
Prev Close $3.50
Price $3.51
Change 0.29%
About

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.71
Mean price target
2. Current target
$3.51
Latest analyst target
3. DCF / Fair value
$-7.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.51
Low
$3.00
High
$11.00
Mean
$6.71

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-26 main B of A Securities Neutral → Neutral $6
2026-02-26 reit Needham Buy → Buy $8
2025-12-17 up JP Morgan Neutral → Overweight $11
2025-09-11 reit Needham Buy → Buy $8
2025-07-08 reit Needham Buy → Buy $8
2025-06-16 main Morgan Stanley Equal-Weight → Equal-Weight $5
2025-05-06 main Needham Buy → Buy $8
2025-04-10 main Morgan Stanley Equal-Weight → Equal-Weight $8
2025-04-08 reit Needham Buy → Buy $11
2025-02-28 main Leerink Partners Market Perform → Market Perform $6
2025-02-06 reit Needham Buy → Buy $11
2025-01-08 main Keybanc Overweight → Overweight $10
2024-12-11 reit Needham Buy → Buy $11
2024-11-20 reit Needham Buy → Buy $11
2024-11-07 reit Needham Buy → Buy $11
2024-09-04 main Needham Buy → Buy $11
2024-09-03 main Jefferies Hold → Hold $6
2024-09-03 main Leerink Partners Market Perform → Market Perform $8
2024-08-09 main Needham Buy → Buy $16
2024-07-11 main Keybanc Overweight → Overweight $12
News
RSS: Latest RXRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-07 BORGESON BLAKE CHARLES Director — 30,000 $3.10 $93,000
2026-04-07 GIBSON CHRISTOPHER Director — 40,000 $3.10 $124,000
2026-04-07 GIBSON CHRISTOPHER Director — 40,000 — —
2026-04-01 LI DEAN Y Director — 3,268 $0.00 $0
2026-04-01 DAR ZAVAIN Director — 4,902 $0.00 $0
2026-03-23 GIBSON CHRISTOPHER Director — 40,000 $3.25 $130,000
2026-03-23 GIBSON CHRISTOPHER Director — 40,000 — —
2026-03-17 TAYLOR BEN R Chief Financial Officer — 7,956 $3.39 $26,971
2026-03-09 GIBSON CHRISTOPHER Director — 20,000 $0.00 $0
2026-03-09 GIBSON CHRISTOPHER Director — 20,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
74.26
+26.96%
58.49
+33.30%
43.88
+10.57%
39.68
Operating Revenue
74.26
+26.96%
58.49
+33.30%
43.88
+10.57%
39.68
Cost Of Revenue
70.95
+56.84%
45.24
+6.22%
42.59
-11.78%
48.27
Reconciled Cost Of Revenue
70.95
+56.84%
45.24
+6.22%
42.59
-11.78%
48.27
Gross Profit
3.30
-75.07%
13.25
+927.93%
1.29
+115.00%
-8.59
Operating Expense
651.43
+32.34%
492.25
+40.10%
351.35
+48.17%
237.13
Research And Development
475.27
+51.16%
314.42
+30.34%
241.23
+54.93%
155.70
Selling General And Administration
176.59
-0.90%
178.18
+60.78%
110.82
+35.81%
81.60
General And Administrative Expense
176.59
-0.90%
178.18
+60.78%
110.82
+35.81%
81.60
Other Gand A
176.59
-0.90%
178.18
+60.78%
110.82
+35.81%
81.60
Other Operating Expenses
-0.42
-21.08%
-0.35
+49.79%
-0.70
-331.48%
-0.16
Total Expenses
722.39
+34.40%
537.49
+36.44%
393.94
+38.03%
285.41
Operating Income
-648.13
-35.31%
-479.00
-36.83%
-350.06
-42.46%
-245.73
Total Operating Income As Reported
-648.13
-35.31%
-479.00
-36.83%
-350.06
-42.46%
-245.73
EBITDA
-559.38
-31.09%
-426.72
-38.71%
-307.63
-35.12%
-227.66
Normalized EBITDA
-559.38
-31.09%
-426.72
-38.71%
-307.63
-35.12%
-227.66
Reconciled Depreciation
83.70
+129.36%
36.49
+49.55%
24.40
+107.57%
11.76
EBIT
-643.09
-38.83%
-463.22
-39.51%
-332.03
-38.68%
-239.42
Total Unusual Items
—
—
0.00
0.00
Total Unusual Items Excluding Goodwill
—
—
0.00
0.00
Special Income Charges
—
—
0.00
0.00
Other Special Charges
—
—
—
—
Net Income
-644.76
-39.06%
-463.66
-41.33%
-328.07
-36.99%
-239.48
Pretax Income
-644.89
-38.75%
-464.79
-39.94%
-332.13
-38.69%
-239.48
Net Non Operating Interest Income Expense
20.98
+47.88%
14.19
-25.41%
19.02
+206.81%
6.20
Interest Expense Non Operating
1.81
+15.14%
1.57
+1520.62%
0.10
+76.36%
0.06
Net Interest Income
20.98
+47.88%
14.19
-25.41%
19.02
+206.81%
6.20
Interest Expense
1.81
+15.14%
1.57
+1520.62%
0.10
+76.36%
0.06
Interest Income Non Operating
22.79
+44.61%
15.76
-17.57%
19.12
+205.66%
6.25
Interest Income
22.79
+44.61%
15.76
-17.57%
19.12
+205.66%
6.25
Other Income Expense
-17.74
-59236.67%
0.03
+102.76%
-1.09
-2190.38%
0.05
Other Non Operating Income Expenses
-17.74
-59236.67%
0.03
+102.76%
-1.09
-2190.38%
0.05
Tax Provision
-0.14
+87.93%
-1.13
+72.26%
-4.06
0.00
Tax Rate For Calcs
0.00
-17.53%
0.00
-80.17%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-644.76
-39.06%
-463.66
-41.33%
-328.07
-36.99%
-239.48
Net Income From Continuing Operation Net Minority Interest
-644.76
-39.06%
-463.66
-41.33%
-328.07
-36.99%
-239.48
Net Income From Continuing And Discontinued Operation
-644.76
-39.06%
-463.66
-41.33%
-328.07
-36.99%
-239.48
Net Income Continuous Operations
-644.76
-39.06%
-463.66
-41.33%
-328.07
-36.99%
-239.48
Normalized Income
-644.76
-39.06%
-463.66
-41.33%
-328.07
-36.99%
-239.48
Net Income Common Stockholders
-644.76
-39.06%
-463.66
-41.33%
-328.07
-36.99%
-239.48
Diluted EPS
-1.44
+14.79%
-1.69
-6.96%
-1.58
-16.18%
-1.36
Basic EPS
-1.44
+14.79%
-1.69
-6.96%
-1.58
-16.18%
-1.36
Basic Average Shares
447.45
+63.18%
274.21
+31.92%
207.85
+18.41%
175.54
Diluted Average Shares
447.45
+63.18%
274.21
+31.92%
207.85
+18.41%
175.54
Diluted NI Availto Com Stockholders
-644.76
-39.06%
-463.66
-41.33%
-328.07
-36.99%
-239.48
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,474.13
+1.76%
1,448.60
+121.60%
653.70
-6.79%
701.29
Current Assets
812.85
+13.80%
714.27
+63.02%
438.14
-23.11%
569.81
Cash Cash Equivalents And Short Term Investments
743.29
+25.06%
594.35
+51.79%
391.56
-28.79%
549.91
Cash And Cash Equivalents
743.29
+25.06%
594.35
+51.79%
391.56
-28.79%
549.91
Other Short Term Investments
—
—
—
0.00
Receivables
24.65
-49.87%
49.17
+1489.08%
3.09
+12.39%
2.75
Accounts Receivable
—
—
—
0.00
Other Receivables
24.65
-49.87%
49.17
+1489.08%
3.09
+12.39%
2.75
Prepaid Assets
11.74
-60.33%
29.60
—
—
Restricted Cash
4.59
+50.87%
3.04
-5.76%
3.23
+152.42%
1.28
Other Current Assets
28.57
-25.04%
38.11
-5.32%
40.25
+153.62%
15.87
Total Non Current Assets
661.28
-9.95%
734.33
+240.66%
215.56
+63.96%
131.47
Net PPE
169.48
-27.33%
233.21
+94.06%
120.17
-1.05%
121.45
Gross PPE
258.69
-12.57%
295.88
+79.27%
165.04
+8.90%
151.56
Accumulated Depreciation
-89.21
-42.35%
-62.67
-39.67%
-44.87
-49.00%
-30.11
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
28.69
+4.85%
27.36
+23.68%
22.13
+9.73%
20.16
Construction In Progress
0.51
-81.17%
2.71
-16.00%
3.23
-63.06%
8.75
Other Properties
158.71
-17.80%
193.08
+105.93%
93.76
+16.07%
80.78
Leases
70.78
-2.68%
72.73
+58.35%
45.93
+9.69%
41.87
Goodwill And Other Intangible Assets
472.06
-2.61%
484.73
+447.72%
88.50
+4100.24%
2.11
Goodwill
162.16
+8.92%
148.87
+185.99%
52.06
+6398.88%
0.80
Other Intangible Assets
309.90
-7.73%
335.86
+821.59%
36.44
+2690.43%
1.31
Non Current Deferred Assets
0.96
-50.52%
1.93
0.00
—
Non Current Deferred Taxes Assets
0.96
-50.52%
1.93
0.00
—
Other Non Current Assets
18.79
+29.98%
14.45
+109.78%
6.89
-13.01%
7.92
Total Liabilities Net Minority Interest
343.26
-17.05%
413.82
+117.50%
190.26
-11.70%
215.48
Current Liabilities
147.71
-21.21%
187.47
+101.21%
93.17
-7.08%
100.27
Payables And Accrued Expenses
56.58
+7.50%
52.63
+90.01%
27.70
+62.40%
17.06
Payables
18.12
-16.17%
21.61
+446.75%
3.95
-13.80%
4.59
Accounts Payable
18.12
-16.17%
21.61
+446.75%
3.95
-13.80%
4.59
Current Accrued Expenses
38.46
+23.99%
31.02
+30.62%
23.75
+90.42%
12.47
Pensionand Other Post Retirement Benefit Plans Current
31.77
-37.52%
50.85
+122.18%
22.89
+12.01%
20.43
Current Debt And Capital Lease Obligation
21.75
-2.10%
22.22
+260.89%
6.16
+1.79%
6.05
Current Debt
9.09
+7.91%
8.43
+20448.78%
0.04
-57.73%
0.10
Other Current Borrowings
9.09
+7.91%
8.43
+20448.78%
0.04
-57.73%
0.10
Current Capital Lease Obligation
12.66
-8.21%
13.79
+125.56%
6.12
+2.76%
5.95
Current Deferred Liabilities
37.60
-39.12%
61.77
+69.57%
36.43
-35.79%
56.73
Current Deferred Revenue
37.60
-39.12%
61.77
+69.57%
36.43
-35.79%
56.73
Total Non Current Liabilities Net Minority Interest
195.56
-13.60%
226.34
+133.12%
97.09
-15.73%
115.22
Long Term Debt And Capital Lease Obligation
56.21
-34.84%
86.27
+93.80%
44.52
-0.98%
44.96
Long Term Debt
9.56
-49.72%
19.02
+1627.70%
1.10
+105.41%
0.54
Long Term Capital Lease Obligation
46.65
-30.64%
67.25
+54.90%
43.41
-2.26%
44.42
Non Current Deferred Liabilities
137.27
+1.42%
135.34
+157.41%
52.58
-25.17%
70.26
Non Current Deferred Revenue
114.01
-4.00%
118.77
+131.79%
51.24
-27.07%
70.26
Non Current Deferred Taxes Liabilities
23.25
+40.30%
16.57
+1137.86%
1.34
0.00
Other Non Current Liabilities
2.08
-56.04%
4.73
—
—
Stockholders Equity
1,130.87
+9.29%
1,034.78
+123.28%
463.44
-4.60%
485.81
Common Stock Equity
1,130.87
+9.29%
1,034.78
+123.28%
463.44
-4.60%
485.81
Capital Stock
0.01
+25.00%
0.00
+100.00%
0.00
+0.00%
0.00
Common Stock
0.01
+25.00%
0.00
+100.00%
0.00
+0.00%
0.00
Share Issued
528.18
+33.11%
396.80
+69.38%
234.27
+22.64%
191.02
Ordinary Shares Number
528.18
+33.11%
396.80
+69.38%
234.27
+22.64%
191.02
Additional Paid In Capital
3,170.14
+28.15%
2,473.70
+72.86%
1,431.06
+27.16%
1,125.36
Retained Earnings
-2,076.00
-45.04%
-1,431.28
-47.92%
-967.62
-51.30%
-639.56
Gains Losses Not Affecting Retained Earnings
36.72
+580.78%
-7.64
0.00
0.00
Other Equity Adjustments
36.72
+580.78%
-7.64
—
—
Total Equity Gross Minority Interest
1,130.87
+9.29%
1,034.78
+123.28%
463.44
-4.60%
485.81
Total Capitalization
1,140.43
+8.22%
1,053.80
+126.85%
464.54
-4.48%
486.34
Working Capital
665.14
+26.26%
526.80
+52.71%
344.97
-26.53%
469.55
Invested Capital
1,149.52
+8.22%
1,062.23
+128.64%
464.58
-4.49%
486.44
Total Debt
77.97
-28.14%
108.49
+114.11%
50.67
-0.65%
51.01
Capital Lease Obligations
59.31
-26.82%
81.05
+63.63%
49.53
-1.67%
50.37
Net Tangible Assets
658.80
+19.77%
550.05
+46.71%
374.94
-22.49%
483.70
Tangible Book Value
658.80
+19.77%
550.05
+46.71%
374.94
-22.49%
483.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-371.81
-3.52%
-359.17
-24.81%
-287.78
-244.55%
-83.52
Cash Flow From Continuing Operating Activities
-371.81
-3.52%
-359.17
-24.81%
-287.78
-244.55%
-83.52
Net Income From Continuing Operations
-644.76
-39.06%
-463.66
-41.33%
-328.07
-36.99%
-239.48
Depreciation Amortization Depletion
83.70
+129.36%
36.49
+49.55%
24.40
+107.57%
11.76
Depreciation And Amortization
83.70
+129.36%
36.49
+49.55%
24.40
+107.57%
11.76
Other Non Cash Items
53.88
+63.50%
32.95
+504.68%
5.45
-36.33%
8.56
Stock Based Compensation
111.22
+36.16%
81.69
+52.68%
53.50
+91.71%
27.91
Asset Impairment Charge
5.96
+5414.81%
0.11
-90.91%
1.19
-57.66%
2.81
Operating Gains Losses
4.50
—
—
—
Change In Working Capital
13.69
+129.27%
-46.76
-5.65%
-44.26
-142.18%
104.92
Change In Receivables
32.94
+642.56%
-6.07
+21.73%
-7.76
-387700.00%
-0.00
Changes In Account Receivables
—
—
—
—
Change In Prepaid Assets
49.86
+669.36%
-8.76
-245.95%
6.00
—
Change In Payables And Accrued Expense
-12.35
-205.65%
11.69
+38.56%
8.44
+392.53%
1.71
Change In Accrued Expense
-9.73
-285.25%
5.25
-44.24%
9.42
+17551.85%
-0.05
Change In Payable
-2.62
-140.65%
6.43
+751.98%
-0.99
-155.86%
1.77
Change In Account Payable
-2.62
-140.65%
6.43
+751.98%
-0.99
-155.86%
1.77
Change In Other Working Capital
-36.77
-31.15%
-28.04
+31.74%
-41.08
-137.23%
110.32
Change In Other Current Liabilities
-19.99
-28.28%
-15.58
-58.00%
-9.86
-38.71%
-7.11
Investing Cash Flow
-16.87
-106.49%
260.06
+2642.62%
-10.23
-105.29%
193.25
Cash Flow From Continuing Investing Activities
-16.87
-106.49%
260.06
+2642.62%
-10.23
-105.29%
193.25
Net PPE Purchase And Sale
-6.47
+52.76%
-13.70
-14.55%
-11.96
+67.74%
-37.06
Purchase Of PPE
-6.47
+52.76%
-13.70
-14.55%
-11.96
+67.74%
-37.06
Capital Expenditure
-8.63
+49.39%
-17.05
-35.80%
-12.55
+66.40%
-37.36
Net Investment Purchase And Sale
-3.81
0.00
-100.00%
0.48
-99.79%
230.61
Purchase Of Investment
-3.81
0.00
0.00
0.00
Sale Of Investment
0.00
0.00
-100.00%
0.48
-99.79%
230.61
Net Business Purchase And Sale
-4.44
-101.60%
277.10
+14927.33%
1.84
0.00
Purchase Of Business
-4.44
0.00
0.00
0.00
Gain Loss On Sale Of Business
4.50
0.00
0.00
—
Net Intangibles Purchase And Sale
-2.16
+35.58%
-3.35
-461.14%
-0.60
-99.00%
-0.30
Purchase Of Intangibles
-2.16
+35.58%
-3.35
-461.14%
-0.60
-99.00%
-0.30
Financing Cash Flow
521.53
+71.49%
304.12
+117.02%
140.13
-9.21%
154.34
Cash Flow From Continuing Financing Activities
521.53
+71.49%
304.12
+117.02%
140.13
-9.21%
154.34
Net Issuance Payments Of Debt
-8.43
-89.75%
-4.44
-479.63%
-0.77
-751.11%
-0.09
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
-8.43
-89.75%
-4.44
-479.63%
-0.77
-751.11%
-0.09
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
-8.43
-89.75%
-4.44
-479.63%
-0.77
-751.11%
-0.09
Net Long Term Debt Issuance
-8.43
-89.75%
-4.44
-479.63%
-0.77
-751.11%
-0.09
Net Common Stock Issuance
528.86
+76.04%
300.42
+134.53%
128.09
-10.87%
143.71
Proceeds From Stock Option Exercised
4.09
-49.74%
8.14
-36.41%
12.81
+19.41%
10.72
Net Other Financing Charges
-3.00
—
—
—
Changes In Cash
132.85
-35.20%
205.00
+229.85%
-157.88
-159.79%
264.07
Effect Of Exchange Rate Changes
18.04
+629.77%
-3.41
-1911.70%
0.19
+161.24%
-0.31
Beginning Cash Position
603.02
+50.22%
401.43
-28.20%
559.11
+89.31%
295.35
End Cash Position
753.92
+25.02%
603.02
+50.22%
401.43
-28.20%
559.11
Free Cash Flow
-380.44
-1.12%
-376.22
-25.27%
-300.33
-148.45%
-120.88
Interest Paid Supplemental Data
—
—
0.10
+74.55%
0.06
Common Stock Issuance
528.86
+76.04%
300.42
+134.53%
128.09
-10.87%
143.71
Issuance Of Capital Stock
528.86
+76.04%
300.42
+134.53%
128.09
-10.87%
143.71
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
Sale Of Business
0.00
-100.00%
277.10
+14927.33%
1.84
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category